Investor Presentation Q1 2018

Investor Presentation First three months of 2018 Slide 46 Novo Nordisk's modern and new generation insulins maintain market share in the USA insulin market USA fast-acting insulin Segment volume USA premix insulin Segment volume USA long-acting insulin Segment volume Levemir® share NovoLogⓇ share NovoLog® Mix 70/30 share TresibaⓇ share tMU tMU tMU CAGR volume¹: 3.3% 80 MI penetration: 83.9% 100% 80 CAGR volume¹: (6.1%) MI penetration: 51.8% CAGR volume¹: 4.2% 100% 80 MI penetration: 74.7% 100% 70 70 70 - 80% 80% 80% 60 60 60 50 - 60% 50 60% 50 60% 40 40 40 30 40% 30 40% 30 40% 20 20 20 20% 20% 20% 10 10 10 0 0% 0% 0 0% 0 Feb 2013 Feb 2018 Feb Feb Feb Feb 2013 2018 2013 2018 1 CAGR for 5-year period; tMU: Thousand mega units Note: US trend data reflect changes to IQVIA data collection coverage and methodology as of January 2012. Modern insulin (MI) penetration is of total segment, ie including human insulin Source: IQVIA monthly MAT Feb, 2018 volume figures changing diabetes® novo nordisk

View entire presentation